BRITAIN has gone fat jab crazy — with sales of Wegovy soaring by more than 2,000 per cent in the past month. Dieters are ...

Dr Shazia Malik - a consultant obstetrician and gynaecologist for The Portland Hospital - discussed the pros and cons of ...

With results from highly anticipated trials of Eli Lilly’s orforglipron and Viking Therapeutics’ VK2735 “underwhelming” ...

People with type 2 diabetes treated with GLP-1 receptor agonists may face a slightly higher risk for eye complications ...

Novo Nordisk (NVO) stock in focus as company decides to cut 2025 bonuses for employees in Denmark amid cost-cutting measures ...

Eli Lilly and Company LLY is a key player in the diabetes and obesity drug market, mainly due to the significant popularity ...

In the wake of weight-loss drugs and the rising importance of health, the iconic cultural brand must double down on its roots ...

No one stays on top forever. It’s a lesson that Ozempic maker Novo Nordisk may be painfully learning about. The Danish ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Patients' vision loss, which is rare according to a new study, is also the subject of multiple lawsuits, including two filed ...

A rumor that pharmaceutical companies behind popular weight-loss and diabetes medications like Ozempic faced lawsuits ...